Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ).
Suzhou Basecare Medical Corporation Limited has obtained national Class III medical device registration from China’s regulator for its pre-implantation genetic testing kit for aneuploidy, which is built on a purely domestically developed high-throughput sequencing platform. The PGT-A kit is aimed at IVF patients over 35, couples with chromosomal abnormalities, those with repeated miscarriages or failed embryo transfers, and families with a history of chromosomal disorders.
By analyzing DNA from embryonic cells to detect chromosomal aneuploidy, the kit supports clinical implantation decisions and is considered a key enabling tool for third-generation IVF technology. The approval marks a breakthrough in fully localizing the equipment, reagents and analysis software chain in China’s assisted reproductive genetic testing field, enhancing the country’s technological independence and offering clinics a more controllable, homegrown testing option.
The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited is a China-based medical device company focused on genetic testing solutions for assisted reproduction. The group develops and commercializes high-throughput gene sequencing platforms and related kits, targeting in vitro fertilization patients and families at risk of chromosomal abnormalities in the domestic healthcare market.
Its products support advanced IVF procedures by enabling pre-implantation genetic testing, helping clinics screen embryos for chromosomal issues before transfer. This positions the company within China’s growing reproductive health and precision medicine sector, where demand for localized, fully domestic testing technologies is increasing.
Average Trading Volume: 173,421
Technical Sentiment Signal: Sell
Current Market Cap: HK$566.2M
For a thorough assessment of 2170 stock, go to TipRanks’ Stock Analysis page.